Skip to main content
. 2023 Jan 10;10:1069898. doi: 10.3389/fpubh.2022.1069898

Table 2.

Chronic self-reported diseases of the 584 participants at baseline, by antibody concentration.

Total n = 585 Antibody concentrations < 15 n = 139 Antibody concentrations ≥15 n = 446 p-value
Multimorbidity 0.410a
0–1 463 (89.2%) 114 (91.2%) 349 (88.6%)
≥2 56 (10.8%) 11 (8.8%) 45 (11.4%)
Diabetes (yes) 28 (4.8%) 5 (3.6%) 23 (5.2%) 0.649a
High blood pressure (yes) 84 (14.4%) 10 (7.2%) 75 (16.8%) 0.004 a
Cardiovascular (yes) 25 (4.3%) 2 (1.4%) 22 (4.9%) 0.089a
Respiratory diseases (yes) 44 (7.5%) 14 (10.1%) 30 (6.7%) 0.199a
Chronic renal failure (yes) 9 (1.5%) 1 (0.7%) 8 (1.8%) 0.693a
Cancer (yes) 11 (1.9%) 1 (0.72%) 10 (2.2%) 0.473a
Autoimmune Diseases (yes) 29 (5.0%) 8 (5.8%) 21 (4.7%) 0.655a
Others (yes) 80 (13.7%) 16 (11.5%) 64 (14.4%) 0.48a

aFisher's exact test.

Statistically significant values are denoted in bold.

Sample size is not constant due to missing data.

Total: Number of comorbidities (n = 519); Diabetes (n = 519); High blood pressure (n = 519); Cardiovascular (n = 519); Respiratory diseases (n = 519); Chronic renal failure (n = 519); Cancer (n = 519); Autoimmune Diseases (n = 519); Others (n = 519).

Antibody concentrations < 15: Number of comorbidities (n = 125); Diabetes (n = 125); High blood pressure (n = 125); Cardiovascular (n = 125); Respiratory diseases (n = 125); Chronic renal failure (n = 125); Cancer (n = 125); Autoimmune Diseases (n = 125); Obesity (n = 125); Others (n = 125).

Antibody concentrations ≥15: Number of comorbidities (n = 394); Diabetes (n = 394); High blood pressure (n = 394); Cardiovascular (n = 394); Respiratory diseases (n = 394); Chronic renal failure (n = 394); Cancer (n = 394); Autoimmune Diseases (n = 394); Others (n = 394).